Trelegy Ellipta vs Breo Ellipta
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Trelegy Ellipta | US Breo Ellipta | |
|---|---|---|
| Generic name | fluticasone/umeclidinium/vilanterol | fluticasone/vilanterol |
| Drug class | Inhaled Corticosteroid + LAMA + LABA | ICS/LABA Inhaler |
| Treats | COPD, asthma | Asthma, COPD |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | GSK |
| Year approved | 2017 | 2013 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $200M | $100M |
| Common side effects | Thrush, Respiratory infections, Headache, Cough | Oral thrush, Throat irritation, Headache, Common cold symptoms |
Trelegy Ellipta
Breo Ellipta
Frequently asked questions
Is Trelegy Ellipta or Breo Ellipta better?
Neither is universally "better." Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Breo Ellipta (fluticasone/vilanterol) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Trelegy Ellipta and Breo Ellipta?
Trelegy Ellipta is a Inhaled Corticosteroid + LAMA + LABA made by GSK, while Breo Ellipta is a ICS/LABA Inhaler made by GSK. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Trelegy Ellipta has the larger estimated TV advertising budget of the two.